by Dr. Greg Fors, Chief Science Officer, Biospec Nutritionals
Cardiovascular disease remains the leading cause of death in the U.S. In 2023, 919,032 people died from cardiovascular disease—about 1 in every 3 deaths (≈ one death every 34 seconds). Heart disease alone accounted for 680,981 deaths. [1]
Clinically, the problem isn’t a lack of “cholesterol awareness.” The problem is that many patients are risk-stratified and treated with an incomplete map of:
(1) atherogenic particle burden
(2) insulin biology, and
(3) vascular inflammation/oxidation
This clinician brief summarizes the high-yield markers I use in practice and a pragmatic, integrative protocol framework for the Biospec clinician family.
1) Cholesterol is essential to life itself. Whereas, atherogenesis is particle retention + arterial injury
LDL-C is a cholesterol mass estimate—not a direct particle count. The more clinically actionable question is:
How many apoB-containing particles are circulating, how “retentive” are they (e.g., Lp(a)), and what is the vascular environment they’re traveling through (insulin resistance, inflammation, oxidation, BP/shear stress)?
A useful framing for patient education: cholesterol is often recruited as part of the body’s repair response; in the wrong environment, retained/modified particles become inflammatory drivers of plaque growth and instability.
2) “Size matters” → upgrade to ApoB early (and aim lower than conventional “high-risk” cut points)
Discordance is common: LDL-C can look acceptable while particle burden remains high—particularly with insulin resistance and hypertriglyceridemia.
ApoB better reflects the number of atherogenic particles and can outperform LDL-C for risk prediction in many settings. [2]
Practical targets (how I discuss this clinically)
Conventional guideline language often highlights apoB ≥130 mg/dL as a “risk-enhancing” level. [3] That is useful for identifying clearly high-risk biology—but it’s not the same thing as an “optimal” prevention target.
Here’s the more prevention-forward framing I use:
Clinical move: ApoB is often the highest-yield “upgrade” beyond the standard lipid panel—especially when triglycerides are trending up.
3) Triglycerides: don’t accept “normal” if you’re practicing prevention
For adults, the common lab “upper limit” for fasting triglycerides is <150 mg/dL (Quest reference range). [4] However, many preventive clinicians consider <100 mg/dL a more desirable target for long-term cardiometabolic risk reduction. [6]
Triglycerides are not just a “side number.” In the right phenotype, they are an early flag for insulin resistance, remnant particle burden, and worsening metabolic terrain.
4) Lp(a): the “sticky” genetic risk enhancer that deserves routine consideration
Lp(a) is a genetically influenced apoB particle with pro-atherogenic and pro-thrombotic biology. Contemporary guidance supports measuring Lp(a) at least once in an adult’s lifetime, especially with family history, premature ASCVD, or unexplained plaque burden. [7]
Clinical move: when Lp(a) is elevated, the downstream strategy is usually intensification of modifiable risk control (ApoB lowering, BP optimization, insulin resistance reversal, inflammation control) rather than “waiting for symptoms.”
5) Homocysteine: stronger signal than most clinicians appreciate—especially in combination
Homocysteine is not just “one more marker.” Elevated homocysteine is associated with higher cardiovascular and all-cause mortality in prospective meta-analyses, including dose-response relationships. [8]
But here’s the key point (and where a functional lens matters): homocysteine becomes more clinically meaningful when it clusters with other risk drivers—insulin resistance, hypertension, smoking/toxin exposure, Lp(a), low omega-3 index, oxidative stress, inflammatory tone. The literature has long discussed interaction with traditional risk factors and the possibility that homocysteine may act as a proximate contributor in the wrong vascular environment. [9]
Clinical move: I treat homocysteine as an actionable part of a risk pattern, not a stand-alone number—especially in patients with family history, vascular calcification, or other “silent inflammation” signals.
6) Oxidation and inflammation are not “soft concepts” in vascular disease
Oxidative modification of apoB particles and endothelial inflammation convert “cargo particles” into immune-activating drivers of foam cell formation and plaque vulnerability. In practice, inflammation control is a core therapeutic pillar—not an optional add-on.
7) Lp-PLA2 activity: vascular-specific inflammation with meaningful risk association
Lp-PLA2 is an inflammatory enzyme linked to plaque biology. Large prospective collaborative analyses show independent associations between Lp-PLA2 mass/activity and coronary outcomes. [10] I view Lp-PLA2 activity as one of the more clinically “readable” vascular inflammation markers—particularly when paired with ApoB and metabolic markers.
How I use it clinically: Lp-PLA2 is not a standalone “diagnosis.” It is a signal of active vascular inflammatory biology, supporting more urgency around ApoB reduction, insulin resistance reversal, BP optimization, and anti-inflammatory strategy.
The Advanced “Biospec Clinician” Risk Panel
Core
High-yield upgrades
Adjunctive (selective)
Biospec Protocol Box: Practical Integrative Support
(Adjunctive to guideline-directed care and medication reconciliation)
Dietary foundation (non-negotiable)
Inflammation modulation*
Omega-3 support (membrane + triglycerides/inflammation context)
Methylation / homocysteine support*
Targeted antioxidant / glutathione support
Insulin resistance support*
Lipid support (ApoB/LDL-C lowering adjunct)*
Mild–moderate hypertension support (adjunct)*
Bottom line
Residual risk is rarely solved by LDL-C alone. The “clinical operating system” is:
Measure the drivers earlier, intervene earlier—and outcomes shift.
*Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
References:
[1] Centers for Disease Control and Prevention. Heart Disease Facts and related CVD mortality statistics (accessed Feb 1, 2026).
[2] De Oliveira-Gomes D, et al. Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice. Circulation. 2024. (Notes ESC/EAS apoB goals <65/<80/<100 mg/dL).
[3] American College of Cardiology. 2018 Cholesterol Guideline “Guidelines Made Simple” Tool: elevated apoB ≥130 mg/dL as a risk-enhancing factor; TG ≥200 mg/dL as a relative indication for apoB measurement (accessed Feb 1, 2026).
[4] Quest Diagnostics. Test Directory: Apolipoprotein B (Optimal <90 mg/dL; Moderate 90–129; High ≥130; treatment target may be <80 depending on risk) and Triglycerides (adult reference <150 mg/dL) (accessed Feb 1, 2026).
[5] European Society of Cardiology / European Atherosclerosis Society. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: apoB secondary goals <65 (very-high risk), <80 (high risk), <100 (moderate risk) (accessed Feb 1, 2026).
[6] Cleveland Clinic. How Triglycerides Impact Heart Health: keep TG <150 mg/dL; “ideally” <100 mg/dL (accessed Feb 1, 2026).
[7] ACC. An Update on Lipoprotein(a): The Latest on Testing, Treatment, and Guideline Thresholds. 2023 (accessed Feb 1, 2026).
[8] Peng H, et al. Elevated homocysteine levels and risk of cardiovascular and all-cause mortality: meta-analysis of prospective studies. 2015.
[9] Ueland PM. The controversy over homocysteine and cardiovascular risk (discussion of interaction with traditional risk factors and mechanistic plausibility). 2000.
[10] Thompson A, et al. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. The Lancet. 2010.
[11] Harris WS, et al. The Omega-3 Index: a new risk factor for death from CHD. 2004.
[12] Dorans KS, et al. Effect of a Low-Carbohydrate Dietary Intervention on Glycemic Control in Adults at High Risk for Type 2 Diabetes. JAMA Network Open. 2022.
[13] Li P, et al. Red Yeast Rice for Hyperlipidemia: meta-analysis of randomized trials. 2022.
[14] Ju J, et al. Efficacy and safety of berberine for dyslipidaemias: systematic review and meta-analysis. 2018.